Citi lowered the firm’s price target on BioNTech (BNTX) to $140 from $145 and keeps a Buy rating on the shares following the Q1 report. The quarter was “muted” on seasonality as expected, the analyst tells investors in a research note. The firm continues to like the BioNTech story citing the company’s multiple oncology platforms. The current valuation remains an attractive entry point, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech SE Reports Q1 2025 Financial Results
- BioNTech’s Earnings Call: Oncology Progress Amid Financial Challenges
- BioNTech price target lowered to $127 from $143 at BofA
- BioNTech price target lowered to $132 from $140 at Morgan Stanley
- BioNTech Reports Q1 2025 Financial Results and Strategic Oncology Advancements